biostudies-literatureHamm SRCarlsbergfondetNovo Nordisk Fonden832501https://www.ebi.ac.uk/biostudies/studies/S-EPMC8905653biostudies-literatureUnknown13<h4>Background</h4>Previous studies have indicated inferior responses to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccination in solid organ transplant (SOT) recipients. We examined the development of anti-receptor-binding domain (RBD) immunoglobulin G (IgG) after two doses of BNT162b2b in SOT recipients 6 months after vaccination and compared to that of immunocompetent controls.<h4>Methods</h4>We measured anti-RBD IgG after two doses of BNT162b2 in 200 SOT recipients and 200 matched healthy controls up to 6 months after first vaccination. Anti-RBD IgG concentration and neutralizing capacity of antibodies were measured at first and second doses of BNT162b2 and 2 and 6 months after the first dose. T-cell responses were measured 6 months after the first dose.<h4>Results</Frontiers in immunologyDecline in Antibody Concentration 6 Months After Two Doses of SARS-CoV-2 BNT162b2 Vaccine in Solid Organ Transplant Recipients and Healthy Controls.PMC8905653NNF20SA0063505Bundgaard HHilsted LMHansen CBGarred PMadsen JRFogh KHeftdal LDPoulsen JRFrikke-Schmidt RPerch MOstrowski SRSorensen EAlmagro Armenteros JJHarboe ZBPries-Heje MMHasselbalch RBSorensen SSKnudsen ADRasmussen APerez-Alos LIversen KHamm SRMoller DLNielsen SDfalseDecline in Antibody Concentration 6 Months After Two Doses of SARS-CoV-2 BNT162b2 Vaccine in Solid Organ Transplant Recipients and Healthy Controls.<h4>Background</h4>Previous studies have indicated inferior responses to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccination in solid organ transplant (SOT) recipients. We examined the development of anti-receptor-binding domain (RBD) immunoglobulin G (IgG) after two doses of BNT162b2b in SOT recipients 6 months after vaccination and compared to that of immunocompetent controls.<h4>Methods</h4>We measured anti-RBD IgG after two doses of BNT162b2 in 200 SOT recipients and 200 matched healthy controls up to 6 months after first vaccination. Anti-RBD IgG concentration and neutralizing capacity of antibodies were measured at first and second doses of BNT162b2 and 2 and 6 months after the first dose. T-cell responses were measured 6 months after the first dose.<h4>Results</2022-01-01T00:00:00Z20222025-04-04T20:23:21.885Z2025-04-04T20:23:21.885ZS-EPMC89056533528102310.3389/fimmu.2022.832501